CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 100 enrolled
Drug / intervention
Durvalumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04416633
NCT04416633Phase 4Completed
CompareCT.gov

A Prospective, Multicenter, Phase-IV Clinical Trial to Assess Safety of Durvalumab in Indian Adult Patients With Locally Advanced, Unresectable Non-small Cell Lung Cancer (NSCLC)

AstraZeneca·interventional·Posted Jun 4, 2020·Updated Nov 8, 2024

In Brief

A Phase 4 clinical trial evaluating Durvalumab for Unresectable Non-small Cell Lung Cancer (NSCLC). Completed, enrolled 100 participants across 12 sites.

Detailed Summary

A prospective, multicenter, Phase-IV clinical trial to assess safety of Durvalumab in Indian adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUnresectable Non-small Cell Lung Cancer (NSCLC)
CountriesIndia
Collaborators--

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedJun 4, 2020
Enrollment StartNov 30, 2021
Primary CompletionOct 27, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.1 years ago

Interventions

Durvalumabdrug

500-mg/120-mg IV